Accéder au contenu
Merck

Human breast cancer metastases to the brain display GABAergic properties in the neural niche.

Proceedings of the National Academy of Sciences of the United States of America (2014-01-08)
Josh Neman, John Termini, Sharon Wilczynski, Nagarajan Vaidehi, Cecilia Choy, Claudia M Kowolik, Hubert Li, Amanda C Hambrecht, Eugene Roberts, Rahul Jandial
RÉSUMÉ

Dispersion of tumors throughout the body is a neoplastic process responsible for the vast majority of deaths from cancer. Despite disseminating to distant organs as malignant scouts, most tumor cells fail to remain viable after their arrival. The physiologic microenvironment of the brain must become a tumor-favorable microenvironment for successful metastatic colonization by circulating breast cancer cells. Bidirectional interplay of breast cancer cells and native brain cells in metastasis is poorly understood and rarely studied. We had the rare opportunity to investigate uncommonly available specimens of matched fresh breast-to-brain metastases tissue and derived cells from patients undergoing neurosurgical resection. We hypothesized that, to metastasize, breast cancers may escape their normative genetic constraints by accommodating and coinhabiting the neural niche. This acquisition or expression of brain-like properties by breast cancer cells could be a malignant adaptation required for brain colonization. Indeed, we found breast-to-brain metastatic tissue and cells displayed a GABAergic phenotype similar to that of neuronal cells. The GABAA receptor, GABA transporter, GABA transaminase, parvalbumin, and reelin were all highly expressed in breast cancer metastases to the brain. Proliferative advantage was conferred by the ability of breast-to-brain metastases to take up and catabolize GABA into succinate with the resultant formation of NADH as a biosynthetic source through the GABA shunt. The results suggest that breast cancers exhibit neural characteristics when occupying the brain microenvironment and co-opt GABA as an oncometabolite.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-GAD67, clone 1G10.2, clone 1G10.2, Chemicon®, from mouse
Sigma-Aldrich
Anticorps anti-protéine acide fibrillaire gliale (GFAP), serum, Chemicon®
Sigma-Aldrich
Anticorps anti-parvalbumine, ascites fluid, clone PARV-19, Chemicon®
Sigma-Aldrich
Anticorps anti-protéine acide fibrillaire gliale, clone GA5, clone GA5, Chemicon®, from mouse
Sigma-Aldrich
Anticorps anti-reeline (mreeline, a.a. 164-496), clone G10, clone G10, Chemicon®, from mouse
Sigma-Aldrich
Anti-SLC6A1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
Sigma-Aldrich
Anti-ABAT antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution